Qlarity Imaging teams with Blackford to improve breast MRI accuracy

Qlairty will merge its AI-powered diagnostic software with Blackford’s centralized imaging platform

Woman talking with a nurse while sitting on a table for an MRI machine

Qlarity Imaging and Blackford have signed a new pact to improve breast magnetic resonance imaging (MRI) accuracy.

QuantX by Qlarity Imaging differentiates benign from malignant breast lesions by synthesizing 34 radiomic features into a single value. The QuantX Score, derived from analysis of proven lesions, indicates the likelihood of malignancy in a specimen. The FDA-cleared artificial intelligence (AI) also assists radiologists with volumetric and surface area measurements.

Per the new deal, Qlarity will integrate its AI diagnostic software with Blackford’s centralized imaging platform to help radiologists and health care systems achieve better clinical outcomes.

The Qlarity-Blackford partnership is also geared toward reducing breast MRI deployment time, costs, maintenance, monitoring, and support requirements.

"Breast MRI evaluations are one of the more difficult exams for radiologists. Factoring in the current challenges contributing to widespread radiologist burnout, the question is not if technological advancements are needed, but how they can be developed and implemented to add the most value," said Jon DeVries, Qlarity Imaging CEO

DeVries added, "Partnering with Blackford will help radiologists and their teams overcome current workflow, budget, and productivity challenges, while also providing unique opportunities for innovation with partners to improve the quality of breast cancer screening and diagnosis strategies."

Related Resource

Preparing for AI-enabled cyber attacks

MIT technology review insights

AI icon against a laptop icon on a yellow background - whitepaper from DarktraceDownload now

Commenting on its tool’s scope, Qlarity stated QuantX is designed for screening patients at high risk for breast abnormalities. QuantX's clinical trials that earned it FDA approval found it reduced missed cancers by 39% and increased clinical accuracy by 20%.

QuantX is not intended for the primary interpretation of digital mammograms. 

"We are delighted that Qlarity's QuantX™ will be available through Blackford's curated marketplace of applications. We look forward to working with Qlarity to provide our customers and channel partners with simplified access to QuantX™ through our dedicated platform, to help drive additional clinical value for patients," said Ben Panter, Blackford Analysis CEO. 

Featured Resources

The definitive guide to warehouse efficiency

Get your free guide to creating efficiencies in the warehouse

Free download

The total economic impact™ of Datto

Cost savings and business benefits of using Datto Integrated Solutions

Download now

Three-step guide to modern customer experience

Support the critical role CX plays in your business

Free download

Ransomware report

The global state of the channel

Download now

Recommended

Allurion launches remote patient weight-loss monitoring service
analytics

Allurion launches remote patient weight-loss monitoring service

21 Sep 2021
OpsRamp offers AIOps-driven predictive alerts
IT infrastructure

OpsRamp offers AIOps-driven predictive alerts

21 Sep 2021
Oracle Fusion Marketing automates lead generation
artificial intelligence (AI)

Oracle Fusion Marketing automates lead generation

20 Sep 2021
Sensome’s AI-powered stroke guidewire begins human trials in Australia
artificial intelligence (AI)

Sensome’s AI-powered stroke guidewire begins human trials in Australia

13 Sep 2021

Most Popular

What are the pros and cons of AI?
machine learning

What are the pros and cons of AI?

8 Sep 2021
The technology powering the future of shopping
Technology

The technology powering the future of shopping

16 Sep 2021
Citrix mulling potential sale after tumultuous 2021
mergers and acquisitions

Citrix mulling potential sale after tumultuous 2021

15 Sep 2021